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Virions of human polyomavirus JC (JCV) are 40–
55 nm in diameter, non-enveloped icosahedrals
with 72 capsomers containing double-stranded
circular genome DNA.1 In the clinical setting, JCV
has been isolated from a patient with progressive
multifocal leukoencephalopathy (PML)2 and it
has also been isolated from the urine of a renal
transplant patient by Horgan et al.3 JCV DNA can
be isolated from urine, and scientists have used
this technique for human polyomavirus research
including research on strains, regionalism, and
evolutionism.
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Background/Purpose: Among the genotypes of human polyomavirus JC (JCV) reported in Taiwan, CY,
TW1, TW2 and TW3 are the most commonly correlated with human diseases. JCV is usually detected
using nucleotide sequencing and restriction fragment length polymorphism (RFLP) analysis. The aim of
this study was to detect the rate of positivity and genotype of the JCV genome in urine by RFLP or capillary
electrophoresis (CE) in renal transplant patients and healthy volunteers.
Methods: We compared CE analysis to the methods of nucleotide sequencing and RFLP analysis for detection
of JCV viruria among 60 renal transplant patients and 50 unrelated healthy controls. Genotyping of the
positive PCR products was performed using CE and RFLP analysis simultaneously.
Results: The urine JCV-positive rate was significantly higher in renal transplant patients than in healthy
volunteers (40% [24/60] vs. 20% [10/50]; p = 0.0238). In addition, multiple genotypes of JCV could be 
detected by CE, but only one genotype could be detected by RFLP. In our study, 20% (2/10) of urine 
JCV-positive samples from healthy volunteers had two different genotypes. In renal transplant patients
66% (16/24) of JCV-positive samples had two different genotypes and 12% (3/24) had three different
genotypes.
Conclusion: In comparison with RFLP, CE can detect multiple genotypes in urine JCV-positive samples
and requires only 1/200 of the volume of specimen required for RFLP analysis. The CE method has sensitivity
and specificity suitable for use in the clinical laboratory, and identifies more genotypes than RFLP analysis.
[J Formos Med Assoc 2008;107(3):239–244]
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ORIGINAL ARTICLE
Previous studies revealed that JCV infection
often occurs in childhood, and most of the first
time infections do not cause clinical signs or they
are not obvious. When JCV infects the urethra or
other organs (including the brain), uremia occurs
in some patients.4,5 JCV is an opportunistic infec-
tion in humans and causes demyelination dis-
eases such as PML.6,7 As we can isolate JCV from
the urine of an infected person, this could be 
because the virus is in the kidneys or is secreted
into the urine from other organs.8,9 When T cell
function declines, the virus becomes active, as evi-
denced by rising virus copy numbers in the serum,
and increasing numbers of virions secreted into the
urine. Virus activation by immunosuppression or
the relationship between JCV activation and im-
munity can be seen in renal transplant patients,3,10
bone marrow transplant patients, pregnant moth-
ers,9,11 cancer patients,3,12 and AIDS patients.13
PML occurs in the brain when patients remain in
a long-term immunosuppressive situation in which
the virus becomes active and new virus strains
come up in the promoter-enhancer regulatory re-
gion and deletion or recombination or replication
of JCV take place.14–18 The original JCV strain,
CY, has three copies of GGGAA pentanucleotide-A
(PA) and two copies of AAAGC pentanucleotide-
B (PB). The PA is located in the regulatory region
of nucleotides 30 to 34 (PA-1), 198 to 202 (PA-
2), and 218 to 222 (PA-3); the PB is located in
nucleotides 188 to 192 (PB-1) and 207 to 211
(PB-2). We have demonstrated that in the three
strains of JCV, there is a PA-3 deletion in TW1 and
PA-2 and PA-3 deletions in TW2. There are also
PB-1 and PA-3 deletions in TW3.
To better understand the relationships between
human JCV genetics and disease, many epidemi-
ologic studies are focusing on infection ability
and virus genotypes in different regions and pop-
ulations.9,19–21 We used polymerase chain reac-
tion (PCR) to detect the existence of JCV in renal
transplant patients and healthy volunteers and
then analyzed the genome type of the infectious
JCV strains.
The traditional way to detect different JCV geno-
mes is by RFLP. However, capillary electrophoresis
(CE) separates DNA by electrophoresis migra-
tion in a capillary tube. The amount of sample is
much less and it is possible to detect several DNA
sequences at one time. Therefore, we compared
CE and RFLP in detection of genotypes in JCV-
positive samples from renal transplant patients
and healthy volunteers.
Methods
Patients and specimens
Urine specimens from different patient groups
(50 subjects who did not receive any immuno-
suppressive agent; mean age, 40 years) and 60
transplant patients (mean age, 39 years; receiving
long-term, high-dose immunosuppressive ther-
apy with tacrolimus [FK 506; Fujisawa, Japan]
2–18 mg/day) were included in JCV screening by
PCR. Single urine specimens were collected in a
sterile container without transport medium and
immediately frozen at −20°C until analyzed.
DNA extraction
Genomic DNA was extracted from urine samples
using the QIAamp DNA blood mini kit (Qiagen,
cat no. 51106, France) according to the manufac-
turer’s instructions.
Amplification of JCV DNA by PCR
PCR primers flanking the region were JCVF-5-
GACATGCCATGGTTTTGCTTTTTGTAGCA-3
(NCBI U61771 nucleotides 4995–5012) with
JCVR-5-GAAGAACCATGGCCAGCTGGTGA-
CAAG-3 (NCBIU61771 nucleotides 241–267).
Genomic JCV DNA (100–200 ng) was subjected to
PCR. The amplification reaction mixture contained
10 X buffer (ABgene, UK) and 0.1 mM of each
primer. Two units of DNA polymerase (ABgene,
UK) were added to each 50-µL PCR reaction mix-
ture. PCR amplification was performed using the
GeneAmp PCR system (Perkin-Elmer Cetus, USA).
The reaction mixture was subjected to denatura-
tion at 94°C for 2 minutes, followed immediately
by 40 cycles of denaturation at 94°C for1 minute,
annealing at 54°C for 1 minute, and extension at
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72°C for 2 minutes. Sequencing primers were the
same as those used for PCR amplification.
Direct autosequencing
Each sequencing reaction mixture consisted of
50 ng of PCR product. After purification, the PCR
product was sequenced using an ABI Prism 310
Automated Genetic Analyzer (Perkin Elmer Ap-
plied Biosystems, USA) and the Big Dye Terminator
Ready Reaction Cycle Sequencing Kit (Perkin Elmer
Applied Biosystems) according to the manufac-
turer’s instructions.
Amplification of JCV genotype by capillary
electrophoresis
The detailed procedure for JCV DNA amplification
and genotyping by CE was as described in the 
literature.22 To determine the number of triplet
repeats in the flanking region of the gene of the
PCR products, the amplified products were dena-
tured for 5minutes at 95°C, mixed with formamide
containing a stop buffer, and electrophoresed on
POP4gels in an automated DNA sequencer (model
310; Applied Biosystems). The number of micro-
satellite repeats was estimated automatically using
the GeneScan software 3.1 (Applied Biosystems)
employing a local Southern blot method, with a
size standard marker of 500 TAMRA (Applied
Biosystems). Five distinct alleles consisting of the
base pair size were designated.
PCR–RFLP
To subtype VP1, PCR products were subjected to
RFLP assay. Ten µL of product was digested with
1 ± 2 U of the appropriate endonuclease (BstN I )
for 2 hours at 60°C, in a total volume of 10 µL of
the supplied buffer. The reaction mixtures were
then subjected to electrophoresis on 5% agarose
gels and the products were detected by ethidium
bromide staining.
Data analysis
Statistical analyses were performed with the aid
of the Epi Info Database and Statistics Software
Program, version 6 (CDC/WHO, Atlanta, GA,
USA).
Results
JCV may be activated and released into the urine
of patients who receive long-term immunosup-
pressant therapy. We collected renal transplant
patients’ urine specimens and compared the 
differences in JCV DNA and genotypes between
patients and healthy subjects (no immunosup-
pression). We collected 60 specimens from renal
transplant patients and another 50 specimens
from unrelated healthy controls. The results
showed that 10 out of 50 (20%) controls and 
24 out of 60 (40%) renal transplant patients were
positive for JCV DNA by PCR (Figure 1).
Using the CE technique, 34 specimens were
positive for JCV in renal transplant patients. Five
out of 24 (21%) renal transplant patients had
single genotypes (either CY, TW1 or TW3); 16 out
of 24 (66%) patients had CY and TW1 genotypes,
or genotypes CY and TW3; and three out of 24
(12%) had three viral genotypes of JCV. In addi-
tion to CY, TW1, or TW2, we also identified the
mutated genotypes of the VP1 region. Among the
healthy people who were positive for JCV, eight
out of 10 (80%) had genotypes CY or TW1; and
only two out of 10 (20%) had multiple genotypes
(Figure 2).
Using RFLP for detecting the 34 urine JCV-
positive specimens from renal transplant patients,
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Figure 1. Urine samples collected from patients for poly-
merase chain reaction screening for shedding of poly-
omavirus JC (JCV).
four single genotypes were found among the pa-
tients and controls: CY, TW1, TW2 , TW3 or others
(Table 1). We compared the DNA replication
templates identified by CE and RFLP showing
obvious variation in DNA replication numbers.
The RFLP technique required DNA templates from
1 ng to 0.1 ng, but CE required only 0.01 ng tem-
plates to perform the analysis (Table 2). We found
mutations occurring in the regulatory regions of
JCV DNA that differed from the original JCV strain.
Discussion
In this study, we found renal transplant patients
have not only an increased rate of JCV infection,
but different genotypes as well. Renal transplant
patients often receive long term immunosup-
pressive agents such as steroids, cyclosporine or
FK-506 to suppress refection. However, at the same
time, these immunosuppressants impair the pa-
tients’ immune response and render them sus-
ceptible to infection. Among these infections, virus
infection is frequently overlooked. Actually, cy-
tomegalovirus and BK virus infection could cause
severe morbidity and even death in renal trans-
plant patients. The development of more sensitive
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Figure 2. Restriction fragment length polymorphism (RFLP) analysis of polyomavirus JC (JCV) samples positive by polymerase
chain reaction (PCR) and capillary electrophoresis (CE) analysis of JCV-positive samples by PCR.
Table 1. Characteristics of genotypes in urinary specimens in renal transplant patients and healthy controls
by capillary electrophoresis
Normal (n = 50) Transplant patients (n = 60) p
Mean age (yr) 40 39
JCV-DNA (−) 40 36 0.0238
JCV-DNA (+) 10 24
Single-genotype 8 5 0.0015
Two-genotype 2 16
Multi-genotype 0 3
Table 2. DNA replication templates by restriction
fragment length polymorphism (RFLP)
and capillary electrophoresis (CE) show
obvious variations in DNA replication
numbers (+ = positive; − = negative)
Sample RFLP CE
1 ng + +
0.1 ng +/− +
0.01 ng − +
and specific methods to detect virus infection is
crucial.
Immunosuppressant therapy such as cortico-
steroid therapy suppresses immune system activity
and alleviates autoimmune disorders. However,
the risk of infection and cancer among these pa-
tients is increased.23,24 There are many reports on
the relationship between virus activation and
immunosuppression.3,4,10,25 The pathogenic mech-
anisms of JCV strains and their related conse-
quences are still under investigation. Tada and
Khalil discovered that one brain-derived DNA
binding protein, lytic control element-binding
protein 1 (LCP-1) binds to the lytic control ele-
ment (LCE; AGGGAAGGGA) to regulate the early
gene expression of JCV in neural glial cells.26 Kumar
et al also found that, in vivo, TGGAAAGCAGCCA
in embryonic carcinoma cells is among the nu-
clear factor 1 (NF-1) motifs,27 and is important
for glial cell-specific expression of JCV. Kumar et al
showed that the GGG region in the LCE is nec-
essary for glial cell-specific transcription. Others
demonstrated that NF-1 in neural glial cells can
bind to nucleotides 207 to 231 in the JCV regu-
latory region,4,28 and this part includes PB-2
(AAAGC) and PA-3 (GGGAA), which may involve
gene regulation of JCV in neural glial cells. Based
on this information, TW1, TW2, and TW3 will not
be activated in neural glial cells because TW1 has
one GGGAA deletion, TW2 has two GGGAA dele-
tions, and TW3 has one GGGAA and one AAAGC
deletion. These genotypes of JCV may infect and
remain in the adrenal cells. According to previ-
ous reports, the renal transplant patients with JCV
infection who take immunosuppressive drugs are
at higher risk of developing PML than healthy in-
dividuals. We hypothesize there is a relationship
between patient immunity and virus genotype. We
wish to have a deeper understanding of reactiva-
tion, infection, and specious differentiation with
the disease.
CE separates DNA by electrophoretic migration
and electro-osmotic flow using a high-voltage elec-
trical field in a capillary tube, with a diameter of
20–200 µm. CE requires no gel making, no run-
ning of polyacrylamide gel electrophoresis, and
can automatically separate PCR products rapidly,
especially for identifying different lengths of
PCR products. This powerful technique enables
differentiation of small changes in DNA sequence
up to 1 bp, which makes it suitable for DNA poly-
morphism analysis.
In conclusion, we have established a simple,
delicate, and accurate method for detecting DNA
viruses requiring very little urine sample volume.
We can use CE to detect 0.01 ng JCV DNA with
genotyping. The further advantage of CE is analysis
of the data by computer to reduce manpower or to
avoid the artificial blind spot. Providing a highly
accurate and delicate platform is beneficial for
future clinical diagnosis of JCV. We can also use CE
for monitoring the reduction of viral load among
renal transplant patients and tracing the virus in
transplant patients. We also believe that CE can
be used to detect other viruses.
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